Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.33 |
| ▸ | CA2 | P00918 | 12/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418672 | 0.81 | PPARG (0.37) | POLB | |
| SCHEMBL4412533 | 0.81 | POLB (0.31) | ALDH1A1CA14POLBPKM | |
| SCHEMBL3140234 | 0.78 | PAX8 (0.42) | CA1CA2ALDH1A1CA14CA12 | |
| SCHEMBL3139946 | 0.75 | PPARA (0.39) | CA1CA2CA4 | |
| SCHEMBL3133683 | 0.74 | POLB (0.38) | ALDH1A1POLBPKM | |
| SCHEMBL3817156 | 0.71 | MEN1 (0.44) | CA1CA2ALDH1A1CA14CA12 | |
| SCHEMBL3817181 | 0.70 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL3819686 | 0.69 | KMT2A (0.48) | CA1CA2ALDH1A1CA12 | |
| SCHEMBL2579003 | 0.69 | CA14 (0.42) | CA1CA14CA12 | |
| SCHEMBL22852725 | 0.68 | CA14 (0.43) | CA1ALDH1A1CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651642-B1 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2009-11-04 | — | — | EP | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| EP-1651642-A4 | PNA MONOMER AND PRECURSOR | PANAGENE INC (KR) | 2006-11-29 | — | — | EP | disclosed |
| EP-1651642-A1 | PNA MONOMER AND PRECURSOR | Panagene Inc. (KR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026930-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009998-A1 | PNA MONOMER AND PRECURSOR | PANAGENE INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026930-A1 | PNA monomer and precursor | RNGTT, POLL, NSUN3 | CA1 1963/4885CA2 3196/4885ALDH1A1 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.